WE TREAT UNTREATABLE CANCERS

At ICCA Global, we specialize in treating late-stage metastatic, recurrent, and primary cancers—conditions often considered 'untreatable' or deemed "palliative" by many cancer centers in the U.S. and Canada.

Our unique approach and expertise make us a beacon of hope for patients seeking alternative treatment options. We utilize next-generation and innovative medicines and therapies that are available globally but often inaccessible to patients in North America. Our treatment process at ICCA Global is designed for comfort, convenience, and results!

Most patients require only two to three weeks of daily outpatient treatment. Following this, patients will undergo a CT scan within five weeks to confirm they are NED (no evidence of disease). As a truly integrative center, we go beyond NCCN guidelines to provide the best treatments worldwide.

Every therapy or medicine used at ICCA Global is either FDA-approved or approved by the government in its country of origin. This allows us to offer personalized, cutting-edge alternative therapies with a higher potential to aid in your healing journey. With affiliates in Southern California and our treatment center located in Baja California, Tijuana, Mexico, we are always at the forefront of integrative care, ensuring that each patient feels valued and important.

Our primary mission is very simple yet life-changing:

1. Restore hope and extend life
2. Alleviate pain
3. Destroy all existing circulating cancer cells
4. Destroy all lethal self-renewing cancer stem cells, which lead to future cancer recurrence
5. Hinder or fully obviate any potential future tumor recurrence
6. Restore your immune system (homeostasis)

FivePoints Cancer Care™, is a proprietary cancer therapy strategy designed to enhance the efficacy and safety of interventions for patients diagnosed with primary or metastatic solid tumors. This regimen incorporates an innovative combination of the following:

Bispecific EpCAM/CD3 Cancer Vaccine Administration

• Designed to stimulate a robust immune response against tumor cells that express the epithelial cell adhesion molecule (EpCAM), which is frequently observed in most adenocarcinomas (colon, breast, stomach, prostate, esophagus, liver, and more).
• Engineered to engage T cells in a targeted manner. By binding to CD3 on T cells and EpCAM on tumor cells, this vaccine directly activates T cells, adeptly directing them to attack and eliminate EpCAM-expressing cancer cells. –
• Targeted intervention enhances anti-tumor immunity and facilitates a coordinated cytotoxic response against the malignancy.

Autologous Lymphocyte Infusion

• Designed to substantially augment the patient's immune system by infusing reactivated and expanded T cells specifically primed against tumor antigens. The administration of activated autologous lymphocytes is intended to enhance the patient's immune response against cancer. The reinvigorated T cells exhibit increased specificity. And cytotoxicity toward tumor cells facilitates a more pronounced immune response against residual cancer cells following the vaccine administration.

Very Short Course Radiation with Chemo-Sensitizing Agent

• The primary objective of this phase is to significantly reduce the overall tumor burden while creating an environment that optimizes the effectiveness of subsequent therapeutic interventions.
• Radiation Therapy: utilizes high-energy radiation to selectively target and damage the DNA of cancer cells within the hepatic metastases. This mechanism leads to cellular apoptosis through direct DNA double-strand breaks. It fosters an immunogenic response, which enhances the visibility of tumor-specific antigens as the irradiated cells undergo immunogenic cell death.
• Chemo-Sensitizing Agent: This agent, which may include compounds such as capecitabine or oxaliplatin, is administered concurrently with radiation therapy to mitigate resistance to radiation by impairing the cancer cell's capacity to repair DNA damage. This synergistic effect amplifies the cytotoxic efficacy of radiation, thereby promoting increased apoptosis in the treated cells.

Allogeneic Natural Killer (NK) Cells:

• Infuses allogenic NK cells to enhance the anti-tumor immune response and mitigate residual cancer cells circulating in the body. NK cells are a crucial part of the innate immune system that can recognize and destroy tumor cells without prior sensitization. They exert their effects by releasing cytotoxic granules that induce apoptosis in cancer cells and producing pro-inflammatory cytokines to further amplify the immune response against tumors. Since NK cells can recognize and attack tumor cells without requiring prior sensitization, they offer a rapid response against malignancies. Combination therapy aims to enhance the immune response to cancer.

NK Cells with Fresh Cord Blood Stem Cells

• Combining fresh cord blood stem cells with allogeneic natural killer (NK) cells represents an innovative approach to cancer treatment, leveraging the unique properties of both cell types. Cord blood stem cells are rich in hematopoietic stem cells, which have the potential to differentiate into various blood cell types, including immune cells.
• Allogenic NK cells, which are derived from a donor, have powerful anti-tumor properties. They play a critical role in the innate immune system by identifying and destroying cancer cells, particularly those that are stressed or infected. When fresh cord blood stem cells are infused into a patient, they can repopulate the immune system and produce new blood cells, including NK cells. By simultaneously administering allogeneic NK cells, the treatment can provide an immediate boost to the patient's immune defense.
• The potential to significantly improve outcomes for patients with various cancers, reassuring us about the future of cancer treatment. Fresh cord blood stem cells help restore the patient's bone marrow and promote the development of a robust immune system, while the allogenic NK cells can more effectively target and eliminate cancer cells.
• Integrating fresh cord blood stem cells with allogenic NK cells is another next frontier in the fight against cancer, aiming to harness the body's immune potential in a multifaceted approach.

Microwave Tumor Ablation (MWA)

• A minimally invasive technique used to destroy solid tumors, offering multiple benefits over conventional surgery; requiring only small incisions or can even be performed percutaneously, leading to less trauma compared to traditional surgical methods.
• The technique specifically targets tumor cells while minimizing damage to surrounding healthy tissue, which can result in fewer side effects.
• The ablation process can be completed relatively quickly, sometimes within 30 minutes or less, making it suitable for outpatient procedures.
• Patients typically experience a quicker recovery than open surgery, allowing them to return to normal activities sooner.
• With smaller incisions and less tissue disruption, patients often report less postoperative pain and smaller, less noticeable scars.
• Microwave ablation can be used for different solid tumors, including those in the liver, kidney, lung, prostate, and breast, making it a versatile treatment option.
• ICCA physicians have experienced nearly 100% favorable tumor destruction and overall survival rates for microwave ablation patients. These benefits make microwave ablation an appealing option for treating solid tumors.

These proprietary protocols are based on scientific principles and the latest ICCA Global clinical applications in cancer treatment. They outline the mechanisms of action, administration guidelines, and monitoring strategies that align with contemporary oncology and immunotherapy practices.